Notable companies
The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Unitedhealth Group (NYSE:UNH), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), ABBVIE (NYSE:ABBV), Abbott Laboratories (NYSE:ABT), Pfizer (NYSE:PFE), Amgen (NASDAQ:AMGN), Intuitive Surgical (NASDAQ:ISRG), Regeneron Pharmaceuticals (NASDAQ:REGN).
Industry description
The investment seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe S&P Health Care Select Sector Half BuyWrite Index.
The index measures the performance of a partially covered call strategy that holds a theoretical portfolio of the securities of the Health Care Select Sector Index. The fund invests in the securities reflected in the index or in investments (including other ETFs) that have economic characteristics that are substantially identical to the economic characteristics of such component securities and cannot invest directly in the index itself. It is non-diversified.
Market Cap
The average market capitalization across the Global X Health Care Cvrd Cll&Gr ETF ETF is 90.04B. The market cap for tickers in the group ranges from 9.7B to 739.66B. LLY holds the highest valuation in this group at 739.66B. The lowest valued company is HSIC at 9.7B.
High and low price notable news
The average weekly price growth across all stocks in the Global X Health Care Cvrd Cll&Gr ETF ETF was 5%. For the same ETF, the average monthly price growth was 28%, and the average quarterly price growth was 44%. ALGN experienced the highest price growth at 12%, while MRNA experienced the biggest fall at -12%.
Volume
The average weekly volume growth across all stocks in the Global X Health Care Cvrd Cll&Gr ETF ETF was -3%. For the same stocks of the ETF, the average monthly volume growth was 25% and the average quarterly volume growth was 7%
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Valuation Rating: 50
P/E Growth Rating: 50
Price Growth Rating: 39
SMR Rating: 61
Profit Risk Rating: 48
Seasonality Score: -38 (-100 ... +100)